125 related articles for article (PubMed ID: 1380608)
41. Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor.
Tikkanen I; Helin K; Tikkanen T; Sybertz EJ; Vemulapalli S; Sariola H; Näveri H; Fyhrquist F
J Pharmacol Exp Ther; 1990 Aug; 254(2):641-5. PubMed ID: 2143536
[TBL] [Abstract][Full Text] [Related]
42. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure.
Liu C; Chen Y; Kang Y; Ni Z; Xiu H; Guan J; Liu K
J Pharmacol Exp Ther; 2011 Oct; 339(1):203-9. PubMed ID: 21737535
[TBL] [Abstract][Full Text] [Related]
43. Increased expression of renal neutral endopeptidase in severe heart failure.
Knecht M; Pagel I; Langenickel T; Philipp S; Scheuermann-Freestone M; Willnow T; Bruemmer D; Graf K; Dietz R; Willenbrock R
Life Sci; 2002 Oct; 71(23):2701-12. PubMed ID: 12383878
[TBL] [Abstract][Full Text] [Related]
44. Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers.
Burnier M; Ganslmayer M; Perret F; Porchet M; Kosoglou T; Gould A; Nussberger J; Waeber B; Brunner HR
Clin Pharmacol Ther; 1991 Aug; 50(2):181-91. PubMed ID: 1831083
[TBL] [Abstract][Full Text] [Related]
45. Renal effects of neutral endopeptidase inhibition in euvolemic and hypervolemic rats.
Scott JM; Barclay PL; Shepperson NB
Eur J Pharmacol; 1993 Sep; 242(1):91-7. PubMed ID: 8223941
[TBL] [Abstract][Full Text] [Related]
46. The blood pressure and renal responses to SCH 34826, a neutral metalloendopeptidase inhibitor, and C-ANF (4-23) in Doca-salt hypertensive rats.
Vemulapalli S; Chiu PJ; Brown A; Griscti K; Sybertz EJ
Life Sci; 1991; 49(5):383-91. PubMed ID: 1649942
[TBL] [Abstract][Full Text] [Related]
47. Natriuretic peptide responses to acute and chronic ventricular pacing in sheep.
Rademaker MT; Charles CJ; Espiner EA; Frampton CM; Nicholls MG; Richards AM
Am J Physiol; 1996 Feb; 270(2 Pt 2):H594-602. PubMed ID: 8779835
[TBL] [Abstract][Full Text] [Related]
48. Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.
Trapani AJ; Beil ME; Coté DT; de Lombaert S; Erion MD; Gerlock TE; Ghai RD; Hopkins MF; Peppard JV; Webb RL
J Cardiovasc Pharmacol; 1994 Mar; 23(3):358-64. PubMed ID: 7515977
[TBL] [Abstract][Full Text] [Related]
49. Augmentation of Natriuretic Peptide Bioactivity via Combined Inhibition of Neprilysin and Phosphodiesterase-9 in Heart Failure.
Scott NJA; Prickett TCR; Charles CJ; Frampton CM; Richards AM; Rademaker MT
JACC Heart Fail; 2023 Feb; 11(2):227-239. PubMed ID: 36752488
[TBL] [Abstract][Full Text] [Related]
50. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
51. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man.
Hunt PJ; Espiner EA; Nicholls MG; Richards AM; Yandle TG
J Clin Endocrinol Metab; 1996 Nov; 81(11):3871-6. PubMed ID: 8923831
[TBL] [Abstract][Full Text] [Related]
52. Renal response to candoxatrilat in patients with heart failure.
Good JM; Peters M; Wilkins M; Jackson N; Oakley CM; Cleland JG
J Am Coll Cardiol; 1995 May; 25(6):1273-81. PubMed ID: 7722120
[TBL] [Abstract][Full Text] [Related]
53. The natriuretic mechanisms of neutral endopeptidase inhibitor in rats.
Shimamoto K; Ura N; Iimura O
Braz J Med Biol Res; 1994 Aug; 27(8):1965-73. PubMed ID: 7749388
[TBL] [Abstract][Full Text] [Related]
54. Low-dose brain natriuretic peptide infusion in normal men and the influence of endopeptidase inhibition.
Florkowski CM; Richards AM; Espiner EA; Yandle TG; Sybertz E; Frampton CM
Clin Sci (Lond); 1997 Mar; 92(3):255-60. PubMed ID: 9093005
[TBL] [Abstract][Full Text] [Related]
55. The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in rats.
Ura N; Shimamoto K; Kuroda S; Nomura N; Iwata M; Aoyama T; Iimura O
Clin Exp Hypertens; 1994 Nov; 16(6):799-808. PubMed ID: 7858560
[TBL] [Abstract][Full Text] [Related]
56. [The effects of the acute administration of atrial natriuretic peptide on the mechanisms regulating diuresis and natriuresis in the essential hypertension patient].
Iannettone CM; Strazzulla G; Fabbri G; Piazza E; Valenza T; De Feo ML; Franchi F
Ann Ital Med Int; 1991; 6(3):273-83. PubMed ID: 1837999
[TBL] [Abstract][Full Text] [Related]
57. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure.
Chen HH; Schirger JA; Chau WL; Jougasaki M; Lisy O; Redfield MM; Barclay PT; Burnett JC
Circulation; 1999 Dec; 100(24):2443-8. PubMed ID: 10595958
[TBL] [Abstract][Full Text] [Related]
58. Role of endogenous atrial natriuretic peptide on systemic and renal hemodynamics in heart failure rats.
Nishikimi T; Miura K; Minamino N; Takeuchi K; Takeda T
Am J Physiol; 1994 Jul; 267(1 Pt 2):H182-6. PubMed ID: 8048584
[TBL] [Abstract][Full Text] [Related]
59. Atrial natriuretic peptide is involved in renal actions of moxonidine.
Mukaddam-Daher S; Gutkowska J
Hypertension; 2000 Jun; 35(6):1215-20. PubMed ID: 10856266
[TBL] [Abstract][Full Text] [Related]
60. Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects.
Riegger GA; Elsner D; Kromer EP; Daffner C; Forssmann WG; Muders F; Pascher EW; Kochsiek K
Circulation; 1988 Feb; 77(2):398-406. PubMed ID: 2962788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
